Document is current

Article History

Received: 27 February 2025

Accepted: 13 August 2025

First Online: 30 September 2025

Declarations

:

: S.Y.M. is a speaker for Astellas. A.L. is an employee of Bayer US LLC, Whippany, NJ, USA. J.A.S. has received grant/research support from AbbVie, Inc., Bayer Healthcare LLC, Mylan/Viatris Inc., and Myovant Sciences; has served as a consultant/on advisory boards for Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., Besins Healthcare, Biote Medical, LLC, Femasys Inc., Mayne Pharma, Inc., Pfizer Inc., and Vella Bioscience Inc; has been on speaker’s bureaus for Ascend Therapeutics, Mayne Pharma, Inc., Myovant Sciences, Inc., and Pharmavite LLC; and is a stockholder (direct purchase) of Sermonix Pharmaceuticals.

: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for this article, take responsibility for the integrity of the work as a whole, and have given their approval of the final draft for submission.

: Medical writing assistance was provided by Charlotte Maddocks of Envision Catalyst, an Envision Medical Communications agency, part of the Envision Pharma Group, and was funded by Bayer Corporation. Envision Pharma Group’s services complied with international guidelines for Good Publication Practice.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.